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Abstract
Retinal organoid technology enables generation of an inexhaustible supply of three-
dimensional retinal tissue from human pluripotent stem cells (hPSCs) for regenerative
medicine applications. The high similarity of organoid-derived retinal tissue and trans-
plantable human fetal retina provides an opportunity for evaluating and modeling ret-
inal tissue replacement strategies in relevant animal models in the effort to develop a
functional retinal patch to restore vision in patients with profound blindness caused
by retinal degeneration. Because of the complexity of this very promising approach
requiring specialized stem cell and grafting techniques, the tasks of retinal tissue deri-
vation and transplantation are frequently split between geographically distant teams.
Delivery of delicate and perishable neural tissue such as retina to the surgical sites
requires a reliable shipping protocol and also controlled temperature conditions with
damage-reporting mechanisms in place to prevent transplantation of tissue damaged
in transit into expensive animal models. We have developed a robust overnight tissue
shipping protocol providing reliable temperature control, live monitoring of the ship-
ment conditions and physical location of the package, and damage reporting at the
time of delivery. This allows for shipping of viable (transplantation-competent) hPSC-
derived retinal tissue over large distances, thus enabling stem cell and surgical teams
from different parts of the country to work together and maximize successful
engraftment of organoid-derived retinal tissue. Although this protocol was developed
for preclinical in vivo studies in animal models, it is potentially translatable for clinical
transplantation in the future and will contribute to developing clinical protocols for
restoring vision in patients with retinal degeneration.
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1 | INTRODUCTION
Shipping and storage of three-dimensional (3-D) retinal tissue dis-
sected for transplantation into the subretinal space of animal models
with retinal degeneration and for clinical trials in patients with retinal
degeneration (CT NCT00346060 and NCT00345917) have previously
utilized Hibernate E medium. This has allowed for successful engraft-
ment of viable tissue (Radtke et al., 2008; Seiler & Aramant, 2012).
Retinal tissue derived from human pluripotent stem cells (hPSCs) is
similar to the transplantable human fetal retinal tissue that was used
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in these clinical trials. The organoid-derived retinal tissue has the dis-
tinct advantage that it can be produced in limitless quantities at differ-
ent stages of retinal development and is currently viewed as a good
candidate for designing a 3-D retinal “patch” to ameliorate vision loss
in advanced retinal degeneration conditions such as age-related macu-
lar degeneration and retinitis pigmentosa (Lin, Mclelland, Mathur, Ara-
mant, & Seiler, 2018; Singh et al., 2015; Singh et al., 2018) and from
retinal trauma. To model these therapies, retinal organoids need to be
derived in a stem cell lab and then shipped to the surgical site for
implantation into animal models. Compared with the logistics of ship-
ping human fetal retinal tissue (which needs to be shipped at low tem-
perature and stored at 4C; Seiler et al., 2008), retinal organoids are
in vitro generated retinal tissue growing in tissue culture media at
37C, and they need no dissection before shipment and benefit from
being shipped under conditions identical or similar to the tissue cul-
ture incubator in the originating stem cell laboratory. Maintenance of
viability and sterility of organoids while shipping and detecting any
potential trauma to the tissues ensures that they are delivered with
maintained viability and ready to implant. This also minimizes variabil-
ity from experiment to experiment and maximizes chances of optimiz-
ing retinal tissue viability for subretinal grafting facilitating the
development of preclinical protocols modeling retinal tissue implanta-
tion in the ocular space for ameliorating vision loss.
Various federal agencies developed guidelines, rules, and regula-
tions for transportation of biological (especially human) specimens,
including Transportation Safety Administration, Federal Aviation
Administration, Department of Transportation, Centers for Disease
Control, Food and Drug Administration, and a number of others.
Because of this, a specialized set of contracted courier companies
evolved driven by the market need to rapidly transport biological sam-
ples via large distances. We were faced with these logistical chal-
lenges while developing a project for large-scale human embryonic
stem (hPSC)–derived retinal tissue testing in vivo in the animal models
with retinal degeneration. We were initially offered services of World
Courier, which is often used for transporting organs for actual trans-
plantation surgeries in patients. However, at $2,000 or more per ship-
ment and the need for optimization of multiple steps (starting from
developing understanding between shipping and receiving teams with
regard to handling the organoids, working out surgical protocol and
development stage of hPSC retinal tissue), this was a very costly
option. Therefore, we developed a simple but very efficient and
robust retinal organoid shipment protocol and a 37C portable ship-
ping container (Figure 1), which is recognized and accepted by FedEx.
This method saves about 85% per shipment (with an average cost of
$300, including the cost of shipping it back by second-day delivery).
The protocol minimizes transportation time, maximizes the viability
and vitality of hPSC retinal tissue for preclinical experiments, is eco-
nomical, and has been used dozens of times by our collaborating
teams over a 2-year period without failure, including when shipping
organoids from California to cold states in winter (e.g., Michigan).
We remove retinal organoids from a stem cell incubator at about
4:00–4:30 p.m. local time, place in a 15-ml tube filled with culture
medium (Singh, Occelli, Binette, Petersen-Jones, & Nasonkin, 2019)
pre-saturated (for 1–2 hr, in the same incubator) with optimized gas
concentrations (CO2 and oxygen), place the tube in the shipping con-
tainer (preequilibrated to reach 37C), which is then placed in a ship-
ping crate recognized by FedEx, with signs “do not X-ray” and “keep
in the upright position,” and deliver the crate to a nearby FedEx ship-
ping facility about 30–45 min before the designated cutoff pickup
time, which may vary between the locations and also depends on the
shipping destination (see protocol below). We use three tracking
devices: two inside the shipper—each reporting temperature condi-
tions inside the shipper, and one additionally reporting the Global
Positioning System (GPS) location and the g-forces inside the shipper;
one tracker is placed outside the shipper to monitor temperature con-
ditions experienced by the 37C shipping container inside the ship-
ping crate. The shipping temperatures drop close to freezing
temperatures outside the shipper when shipping in winter (outside
tracker), whereas inside the container, the temperature fluctuates
between 33C and 36C (which we found acceptable and not
impacting viability of hPSC retinal tissue). The package is delivered to
the designated location by 10:30 a.m. (although 7:30 a.m. delivery
time is also an option, if the organoids are to be transplanted on the
same day), and following delivery, the organoids are placed in a tissue
culture incubator (either on a shaker or into ultra-low adhesion dishes)
until their use in surgery (typically in 1–2 days after delivery). Collec-
tively, our approach maximizes the viability of retinal organoids for
subsequent surgical procedures, optimizes the environment for the
organoids during shipping, and enables us to identify if the package
suffers severe g-forces during delivery that could damage the retinal
organoids. This reduces the risk of using compromised tissues for
implantation, thus optimizing the outcomes, saving valuable animals
and resources, and, collectively, streamlining the development of pre-
clinical protocols aimed at restoring vision by retinal tissue
replacement.
2 | DESIGN OF PORTABLE SHIPPER
We use a battery-driven portable shipper with 0.028-m3 (U.S. 4 ft3)
capacity (manufacturer: Uline, Part Number S-20589, Model Number
20589), external dimensions [L ×W × H] 70.87 × 52.3 × 38.74 cm (U.
S. 27.9 × 20.6 × 15.25 in.), and internal dimensions 66.04 × 48.26 ×
35.56 cm (U.S. 26 × 19 × 14 in.; Figure 1b). We also use two types of
tracking devices: the multiuse SpotBot Cellular (ShockWatch, Austra-
lia; Figure 1c) and multiuse TempTale Ultra (Sensitech, Beverly, MA,
USA; Figure 1d), to report the Global Positioning System (GPS) loca-
tion, g-forces, and temperature remotely (SpotBot) and temperature
only (as a backup, TempTale Ultra). The SpotBot tracker allows live
monitoring of the container's location (except when it is on the plane)
and proactive tracking if it was subjected to excessive g-forces and
even the direction of these forces (e.g., vertical vs. horizontal shaking,
Figure 1h). Although it is not critical for organoid shipment (because
they are shipped as a suspension culture), it may negatively impact
the adherent monolayer cultures of retinal progenitors. The mono-
layers of retinal (and any neural) progenitors differentiated from
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F IGURE 1 37C Shipping container and trackers. (a) Shipping crate with mandatory sticker “UN3373” (Category B biological substance), “do
not X-ray,” and “up” arrows (to emphasize package orientation). (b) Portable 37C incubator from Uline, Part Number S-20589, Model Number
20589. (c) SpotBot live temperature, GPS, and g-force tracker, which allows live monitoring of the package location, temperature conditions, and
g-forces acting in the x-y-z orientations. (d) Multiuse TempTale Ultra temperature tracker, which enables analysis of the detailed temperature
profile changes during each shipment but only after data are downloaded (needs company's software). (e) Portable 37C incubator from Uline in a
shipping crate. (f) Diagram of a portable 37C incubator from Uline prepared for shipment (f-1, motor housing; f-2, temperature reader, sensitive
to mechanical damage; f-3, four to six Cameron's Hot/Cold Gel PakTM, which absorb 37C temperature during incubator-prewarming step [ahead
of shipment] and then provide temperature backup if the battery runs out of power on an especially cold day; f-4, 15-ml tissue culture tube with
retinal organoids, loaded with CO2- and oxygen-presaturated media [the same media and gas conditions used for organoid culture] and placed in
horizontal position, maybe further secured to Gel Pak to guarantee stability; f-5, SpotBot tracker; f-6, multiuse TempTale Ultra temperature
trackers; f-7, an additional layer of insulation [we use camping gear such as sleeping bag] between the Portable 37C incubator and the shipping
crate to (a) eliminate bouncing during shipment and (b) critically preserve battery charge on an especially cold day; f-8, additional padding,
protecting the housing and the temperature indicator against mechanical damage). (g) Geomap (Google Maps) built by SpotBot and mapping (live)
movement of the package (except for when it is on the plane; connecting it to the plane Wi-Fi may provide fluent updates of movement and
shipment conditions during the flight, but we have not tried it). (h) Impact map during shipment (g-forces acting on the package in x-y-z
orientation). The SpotBot will alert the receiving side if an unusually high g-force was experienced by the shipper during transportation (e.g., if it
was dropped). (i) Typical TempTale Ultra temperature profile, downloaded after shipment. (j) Retinal organoids (line H1 = WA01 shipped inside
portable 37C incubator)
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hPSCs have clusters of cells of all shapes and sizes, in addition to sin-
gle cells growing in a dense monolayer and with tight adhesion to
each other (Hambright et al., 2012; Nasonkin et al., 2009; Nasonkin &
Koliatsos, 2006; Singh et al., 2015). Strong forces (e.g., when a box is
dropped) during shipment may dislodge clumps of cells and sometimes
even part of a monolayer (our observation). For organoids, lateral
forces are helpful and move organoids around in the horizontal direc-
tion (when a tube is placed horizontally, Figure 1f), enabling aeration
and preventing adhesion to each other. When a tube with organoids
is shipped in a vertical position, organoids aggregate at the bottom
and frequently stick to each other (likely because of the expression of
neural cell adhesion molecule, typical for all developing neural cells),
which causes problems during transplantation and loading of cannula/
transplantation device (Singh et al., 2019). Using the SpotBot device,
we were able to pinpoint one location where the package was sub-
jected to excessive g-forces repeatedly and address this issue. The
TempTale Ultra temperature trackers serve as an auxiliary tempera-
ture recorders and provide a detailed temperature plot (Figure 1i) but
only after downloading data from them (not live). For all shipments,
we place the shipping container in the same shipping crate. The latter
meets FedEx requirements and is pretested (i.e., accepted) by FedEx
for shipment by air. The crate bears several shipping indicator stickers:
“UN3373” (Category B biological substance), “do not X-ray,” and “up”
arrows (to emphasize package orientation). The UN3373 sticker is
required under the International Air Transport Association shipping
guidelines to meet federal shipping regulations (Figure 1a). The ship-
per is placed inside the crate and further insulated from cold tempera-
tures (we use insulation used in camping gear, which works great) and
mechanical stress (bubble wrap) during shipment (Figure 1e), which
extends battery life in winter. The housing, which includes a tempera-
ture reader (Figure 1f-1) and the fan (Figure 1f-2), is sensitive to
mechanical forces and is a critical part of the shipper, necessary for
temperature control and circulation during shipment.
3 | ORGANOID PREPARATION FOR
SHIPPING
1. Saturate 15 ml of retinal organoid medium (Singh et al., 2019) in a
5% CO2 incubator for 1 hr using a 100-mm tissue culture dish
(rather than 15-ml tube) to maximize saturation of media in the
minimum amount of time (normoxia conditions were used, but per-
centage of oxygen inside the tissue culture incubator may vary;
therefore, it is best to saturate media with percentage of oxygen
and CO2 used for the organoid culture).
2. Transfer saturated media into 15-ml tissue culture tube, add
organoids, add basic fibroblast growth factor (bFGF) and brain-
derived neurotrophic factor (BDNF; 20 ng/ml each, Peprotech,
Rocky Hills, NJ, USA, or R&D Systems, Minneapolis, MN, USA),
close the cap, seal with parafilm (with the sterile side facing the
tube), put a layer of prewarmed heat-absorbing pouches
(Cameron's Hot/Cold Gel PakTM, Figure 1f-3), and place the 15-
ml tube with organoids horizontally into the shipper (Figure 1f-4).
3. Place the SpotBot tracker (Figure 1f-5) and one of the TempTale
Ultra trackers (Figure 1f-6) inside and activate them according to
manufacturer's instructions.
4. Place the other TempTale Ultra tracker outside the shipper (Fig-
ure 1f-6) in the blue bin and activate.
5. Cover with a cloth/insulation material, enabling easy temperature
circulation within the shipper and preventing the tube from bounc-
ing in the shipper.
6. Insulate the shipper inside the crate (Figure 1f-7) and especially
the housing with robust layer of insulation (Figure 1f-8) to reduce
mechanical damage and battery drain.
7. Remove retinal organoids (shaking slowly inside 37C tissue cul-
ture incubator) at about 1 hr before the nearby FedEx shipping
facility closes and ship by “priority overnight” service for delivery
by 10:30 a.m. the next day (which is usually 9:00–9:30 a.m. the
next day local time). We experimented with 7:30 a.m. delivery
the next day (which is an option too) but found it unnecessary. The
movement of the package can be monitored from a smart phone
or desktop computer using SpotBot software, Figure 1g), unless
the package is on the FedEx plane (in the air). This protocol has
been successfully tested and used for over 2 years for shipping ret-
inal organoids (Figure 1j) to two surgical sites at Michigan State
University (East Lansing, MI, USA, including the coldest times in
winter) and University of California Irvine (Irvine, CA, USA) without
any impact on organoid viability (Figure 2) and also retinal progeni-
tors dissociated from retinal organoids (to MSU, UTHSCSA, San
Antonio, TX, USA, and EYECRO, Oklahoma City, OK, USA).
4 | VIABILITY OF TISSUE AND CELLS
AFTER SHIPMENT
Each time, the cultures on arrival were 100% viable (judging by trypan
blue staining), and the cells attached to the flasks. When shipping cells
in flasks, it is essential to fill the flasks completely with media and seal
the caps with sterile parafilm. SYTOX® green (ThermoFisher, Wal-
tham, MA, USA) staining works very accurately for retinal progenitors
dissociated from retinal organoids (as a quick assay for evaluating the
viability). As for retinal organoids, SYTOX® green staining provides a
good pilot estimate of organoid viability (after 30-min staining proce-
dure, according to manufacturer's instructions) but not the absolute
numbers of dead cells, due to incomplete penetration into the core of
the organoid. For exact estimates of the number of dead cells, we rou-
tinely use immunohistochemistry.
To demonstrate the viability of hPSC-derived retinal tissue
(organoids) following this shipping protocol, we evaluated cell death in
retinal organoids before and after overnight shipping by
(a) immunohistochemistry with cleaved Caspase-3 (Cell Signaling, Cat.
#9664, Figure 2, middle panel) and (b) SYTOX® green staining (Fig-
ure 2, bottom panel). In both cases, we found the number of cells pos-
itive for cell death negligible, about 1% or less. To address the
consistency of successful survival of retinal organoids during ship-
ment, we processed (with immunohistochemistry to cleaved Capase-
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F IGURE 2 Cleaved Caspase-3 and SYTOX® green markers in organoids shipped overnight at 37C. Cleaved Caspase-3 and SYTOX® green
markers in organoids shipped overnight at 37C. Evaluating cell death in human pluripotent stem cell retinal tissue (retinal organoids) after overnight
shipment in our 37C shipper by two methods: frozen immunohistochemistry with cleaved Caspase-3 (early cell death marker) antibody and
SYTOX® green staining. (a–c) Retina-specific staining with antibodies to CHX10, RAX, and PAX6, respectively, and pan-nuclear DAPI counterstain.
(d–f) Typical distribution of cleaved Caspase-3 in retinal organoids after overnight shipping procedure (the pattern before and after shipping was
identical); insets represent magnifications of areas shownwith asterisks in the Panels (e) and (f). (g–i) Evaluating cell death in the cultured whole
retinal organoids after shipment with SYTOX® green dead cell stain (impermeant to live cells), 1:10,000 dilution for 30 min: (g) is SYTOX® green
only, (h) is a brightfield image and (i) is a merged image (green+brightfield). (j) A box plot showing the distribution of percentages of cell death [+]
marker cleaved Caspase-3 in four sets of shipped organoids (orange, gray, yellow, and green boxes) in addition to organoids before shipment (blue
box). Very similar percentage of cleaved Caspase-3 was found in all five samples (blue box = organoids before shipping: 0.93%, SEM 0.15; orange,
gray, yellow, and green boxes = organoids after shipping, 0.85%, SEM 0.01; 1.1%, SEM 0.06; 1.07%, SEM 0.08; and 0.98%, SEM 0.09, respectively)
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3) a total of four sets of organoid samples shipped to surgical sites.
These were unused (leftover) organoids, which were fixed by the sur-
gical team and shipped to us after surgeries. We used the box plot
(Figure 2j) to visually show the distribution of percentages of cell
death [+] marker cleaved Caspase-3 in each set. We see very similar
percentage of cleaved Caspase-3 in all five samples (blue box =
organoids before shipping: 0.93%, SEM 0.15; orange, gray, yellow,
and green boxes = organoids after shipping, 0.85%, SEM 0.01; 1.1%,
SEM 0.06; 1.07%, SEM 0.08; and 0.98%, SEM 0.09, respectively). The
analysis of variance (ANOVA) showed no statistically significant differ-
ence in the number of cleaved Caspase-3 [+] cells in all five samples.
An additional observation, which we routinely used for evaluating the
successful delivery of retinal organoids, was (a) lack of cell debris in
the culture and (b) survival of leftover organoids (left after surgeries)
in tissue culture for a week or more and, importantly, successful
in vivo engraftment in subretinal space. The number of cleaved
Caspase-3 [+] cells in retinal organoids (before and after shipment)
was similar to those reported in an earlier study that generated retinal
organoids (Zhong et al., 2014). This clearly demonstrates that the
shipping protocol we have developed robustly maintains the viability
of the hPSC-derived retinal tissue. Furthermore, we report that the
SYTOX® green method can be efficiently used to quickly evaluate
the viability of retinal organoids after shipping and ahead of surgery
(by sampling the subset of organoids, assigned for testing and not sur-
gery with 30-min SYTOX® green assay). This, in turn, ensures that ret-
inal tissue from organoids subjected to harsh shipping conditions is
identified and not used for implantation into animals, thus
streamlining in vivo work and guaranteeing better and more reproduc-
ible results. We recommend testing SYTOX® green on the whole reti-
nal organoids and following the recommended dilutions provided by
the manufacturer (1:10,000–1:30,000). As a positive control, precut
retinal organoids, which have spent several hours outside of the tissue
culture incubator, repeatedly displayed evidence of excessive cell
death when stained with SYTOX® green.
Developing preclinical vision restoration protocols based on
transplanting stem cell–derived retinal tissue (Lin et al., 2018; Singh
et al., 2019) or cells (Hambright et al., 2012) into the ocular space
(subretinal or epiretinal) of experimental animals requires close coordi-
nation of work between the team generating the organoids and the
team doing surgical grafting. Precise and reliable methods are needed,
because (a) biological material is expensive and takes time to generate,
(b) the surgical team, equipment, and surgical rooms are scheduled in
advance and availability of all three takes time to plan, and
(c) critically, the animals, especially those models with progressive reti-
nal atrophy (Petersen-Jones & Komaromy, 2015; Seiler et al., 2014),
are scheduled for surgeries on specific days depending on the dynam-
ics of retina degeneration and multiple experiments are usually done
before each study is completed (with each cohort of animals being
implanted at the same age, to be able to pool the data from multiple
experiments). Developing neural retinal tissue is sensitive to shipping
conditions and needs to be transported quickly and in the optimal
conditions to maintain viability ahead of transplantation. Therefore, if
hPSC retinal tissue (organoids) arrives damaged, this is costly and
impacts the project. This is especially true with large animal models,
and one failed experiment may delay results for the next 3–6 months
(due to breeding constraints). To address this logistical problem in pre-
clinical translational work, we reviewed all available options for over-
night long-distance shipping of viable hPSC retinal tissue for
transplantation and developed and refined this protocol, thus enabling
predictable, cost-effective, and reliable delivery of viable hPSC retinal
tissue. Optimal tissue viability is essential for the overall reproducibil-
ity and success of the in vivo work. This method works equally well
for shipping hPSC retinal tissue and cultured neural retinal progeni-
tors. It will be applicable for teams doing in vitro and in vivo work at
different locations, for precise coordination of tissue shipping, receiv-
ing, and implantation.
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